Pannexin 1 Inhibitor
Pannexin 1 Inhibitor - Related Videos
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
0 Views •
Cited by 2 •
2024
This study illustrates the methodological potential of combining Yttrium-90 Trans-Arterial Radioembolization (Y-90 TARE) with an anti-PD-1 monoclonal antibody as an effective neoadjuvant strategy leading to hepatectomy in hepatocellular carcinoma (HCC) patients with a high initial recurrence risk. It emphasizes the safety, feasibility, and step-by-step procedural guidance of this approach.
08:33
Nucleocapsid Annealing-Mediated Electrophoresis (NAME) Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors
0 Views •
Cited by 8 •
2015
This protocol describes NAME, an assay that allows the rapid identification of molecules able to inhibit in vitro the chaperone activities of HIV-1 nucleocapsid protein.
01:52
Eukaryotic Transcription Inhibitors
0 Views •
2020
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells. Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
0 Views •
2025
This protocol describes a blockade assay for PD-1/PD-L1 inhibitors using surface plasmon resonance technology. It employs a dual-step immobilization strategy and a tailored buffer system to accurately measure response units, facilitating the assessment of blockade rates for compounds or biologics. Additionally, it supports the high-throughput identification of PD-1/PD-L1 inhibitors.
04:00
Modelling Intratumoral Treatment with miRNA Inhibitors: A Method to Analyze the Effect of miRNA Inhibitors on Tumor Growth in Murine Model
0 Views •
2023
This video demonstrates the in vivo delivery of miRNA inhibitors as therapeutic agents against tumor growth in orthotopic mouse models. The intratumoral administration of synthetic miRNA inhibitors or antagomiRs allows them to bind and inhibit endogenous miRNAs, thereby causing mRNA upregulation and suppression of tumor growth.
FAQs
Reducing pannexin 1 channel opening can limit the movement of ATP from cells into the extracellular environment. This changes the availability of an important signaling molecule outside the cell and allows investigators to examine how extracellular purinergic communication contributes to inflammatory responses, rather than treating those responses as independent of channel activity.
ATP can function as an extracellular signal that helps connect cellular activity with surrounding immune responses. When an inhibitor reduces ATP passage associated with pannexin 1 activity, researchers can assess whether changes in inflammation or host response are linked to altered purinergic communication. This makes ATP-related signaling a useful mechanistic focus in infection research.
The inhibitor provides a pharmacological comparison in which pannexin 1 activity is reduced while the broader experimental system remains under study. If an inflammatory or host-response feature changes under this condition, researchers can evaluate whether pannexin 1-dependent signaling contributes to it. The approach therefore helps separate channel-related effects from mechanisms that do not require pannexin 1.
Researchers can compare immune or infection-related responses in the presence and absence of the inhibitory agent. Interpreting the resulting differences requires attention to the specific response being measured, such as inflammatory pathway activity or host-cell behavior. These comparisons help determine whether the observed process is sensitive to reduced pannexin 1 signaling rather than merely associated with it.
This tool is useful when investigators want to test whether pannexin 1 participates in an inflammatory pathway, an infection-related host response, or purinergic communication between cells and their surroundings. It can also support studies of disease mechanisms by showing whether reducing channel activity changes the response under investigation, making the channel a more specific experimental focus.
Results can indicate whether modulating pannexin 1 has a meaningful relationship to inflammatory or infectious disease mechanisms. A response to inhibition may support further investigation of the channel as a therapeutic target, while little or no change can suggest that the pathway is not central in that context. These agents are therefore research tools for evaluating therapeutic possibilities, not conclusions by themselves.